Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

NCT01356290 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.

NCT NCT01356290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01356290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Lead sponsor
Medical University of Vienna
Phase
Phase 2
Overall status
Recruiting
Start date
April 30, 2014
Completion date
April 30, 2030
Enrollment
232 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

atrt recurrent, ependymoma recurrent, medulloblastoma recurrent, rare cns tumor recurrent